Cancer prevention and therapy in a preclinical mouse model: Impact of FHIT viruses

Current Gene Therapy

Volumn 4, Issue 1, 2004, Pages 53-63

  Ishii, Hideshi ^a,b   Vecchione, Andrea ^a   Fong, Louise Y Y ^a   Zanesi, Nicola ^a   Trapasso, Francesco ^a   Furukawa, Yusuke ^b   Baffa, Raffaele ^a   Huebner, Kay ^a   Croce, Carlo M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; FRAGILE HISTIDINE TRIAD PROTEIN;

ANIMAL MODEL; APOPTOSIS; CANCER; CANCER CELL; CANCER GENETICS; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CHROMOSOME DELETION; CHROMOSOME FRAGILE SITE; GENE INACTIVATION; GENE LOSS; GENE THERAPY; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ACID ANHYDRIDE HYDROLASES; ANIMALS; APOPTOSIS; CARCINOGENS, ENVIRONMENTAL; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME FRAGILE SITES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; MICE; MUTATION; NEOPLASM PROTEINS; NEOPLASMS;

EID: 3042720217     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566523044578031     Document Type: Review

References (113)

1. Baffa, R., Veronese, M.L., Santoro, R., Mandes, B., Palazzo, J.P., Rugge, M., Santoro, E., Croce, C.M. and Huebner, K. (1998) Loss of FHIT expression in gastric carcinoma. Cancer Res. 58: 4708-4714.
2. Baffa, R., Gomella, L.G., Vecchione, A., Bassi, P., Mimori, K., Sedor, J., Calviello, C.M., Gardiman, M., Minimo, C., Strup, S.E., McCue, P.A., Kovatich, A.J., Pagano, F., Huebner, K. and Croce, C.M. (2000) Loss of FHIT expression in trasitional cell carcinoma of the urinary bladder. Am. J. Pathol. 156: 419-424.
3. Baylin, S. and Bestor, T.H. (2002) Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1: 299-305.
4. Blot, W.J. (1994) Esophageal cancer trends and risk factors. Semin. Oncol. 21: 403-410.
5. Brenner, C., Bieganowski, P., Pace, H.C. and Huebner, K. (1999) The histidine triad superfamily of nucleotide-binding proteins. J. Cell Physiol. 181: 179-187.
6. Brenner, C. (2002) Hint, Fhit and GalT: function, structure, evolution and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry 41: 9003-9014.
7. Burke, L., Khan, M.A., Freedman, A.N., Gemma, A., Rusin, M., Guinee, D.G., Bennett, W.P., Caporaso, N.E., Fleming, M.V., Travis, W.D., Colby, T.V., Trastek, V., Pairolero, P.C., Tazelaar, H.D., Midthun, D.E., Liotta, L.A. and Harris, C.C. (1998) Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res. 58: 2533-2536.
8. Campiglio, M., Pekarsky, Y., Menard, S., Tagliabue, E., Pilotti, S. and Croce, C.M. (1999) FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res. 59: 3866-3869.
9. Capuzzi, D., Santoro, E., Hauck, W.W., Kovatich, A.J., Rosato, F.E., Baffa, R., Huebner, K. and McCue, P.A. (2000) Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 88: 24-34.
10. Carlton, P. S., Kresty, L.A., Siglin, J.C., Morse, M.A., Lu, J., Morgan, C. and Stoner, G.D. (2001) Inhibition of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus by dietary freeze-dried strawberries. Carcinogenesis 22: 441-446.
11. Caselli, M., Marchisio, M., Gaudio, M., Saragoni, L., Lanza, G., Alvisi, V., Bertagnolo, V., Concu, M., Capitani, S. and Caramelli, E. (2001) Fhit protein expression in human gastric cancer and related precancerous lesions. Oncol. Rep. 8: 1233-1237.
12. Chang, K. W., Kao, S.Y., Tzeng, R.J., Liu, C.J., Cheng, A.J., Yang, S.C., Wong, Y.K. and Lin, S.C. (2002) Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J. Pathol. 196: 300-306.
13. Chang, Y.T., Wu, M.S., Chang, C.J., Huang, P.H., Hsu, S.M. and Lin, J.T. (2002) Preferential loss of Fhit expression in signet-ring cell and Krukenberg subtypes of gastric cancer. Lab. Invest. 82: 1201-1208.
14. Chaudhuri, A.R., Khan, I.A., Prasad, V., Robinson, A.K., Luduena, R.F. and Barnes, L.D. (1999) The tumor suppressor protein Fhit. A novel interaction with tubulin. J. Biol. Chem. 274: 24378-24382.
15. Cohen, A.J., Li, F.P., Berg, S., Marchetto, D.J., Tsai, S., Jacobs, S.C. and Brown, R.S. (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N. Engl. J. Med. 301: 592-595.
16. Coia, L.R. (1994) The esophagus. In: Moss Radiation Oncology: Rationale, Techniques, Results, Mosby-Year book, St. Louise.
17. Corbin, S., Neilly, M.E., Espinosa, R. 3rd., Davis, E.M., McKeithan, T.W., Le Beau, M.M. (2002) Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res. 62: 3477-3484.
18. Croce, C.M. (1999) Role of TCL1 and ALL1 in human leukemias and development. Cancer Res. 59(7 Suppl:): 1778s-1783s.
19. Druker, B.J., Sawyers, C.L., Capdeville, R., Ford, J.M., Baccarani, M. and Goldman, J.M. (2001) Chronic myelogenous leukemia. Hematology (Am. Soc. Hematol. Educ. Program): 87-112.
20. Dumon, K.R., Ishii, H., Fong, L.Y.Y., Zanesi, N., Fidanza, V., Mancini, R., Vecchione, A., Baffa, R., Trapasso, F., During, M.J., Huebner, K. and Croce, C.M. (2001a) FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA 98: 3346-3351.
21. Dumon, K.R., Ishii, H., Vecchione, A., Trapasso, F., Baldassarre, G., Chakrani, F., Druck, T., Rosato, E.F., Williams, N.N., Baffa, R., During, M.J., Huebner, K. and Croce, C.M. (2001b) Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res. 61: 4827-4836.
22. During, M.J., Symes, C.W., Lawlor, P.A., Lin, J., Dunning, J., Fitzsimons, H.L., Poulsen, D., Leone, P., Xu, R., Dicker, B.L., Lipski, J. and Young, D. (2000) An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287: 1453-1460.
23. During, M.J., Xu, R., Young, D., Kaplitt, M.G., Sherwin, R.S. and Leone, P. (1998) Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat. Med. 4: 1131-1135.
24. Fang, J.M., Arlt, M.F., Burgess, A.C., Dagenais, S.L., Beer, D.G., Glover, T.W. (2001) Translocation breakpoints in FHIT and FRA3B in both homologs of chromosome 3 in an esophageal adenocarcinoma. Gene. Chrom. Cancer 30: 292-298.
25. Fero, M.L., Randel, E., Gurley, K.E., Roberts, J.M. and Kemp, C.J. (1998) The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180.
26. Fong, L.Y. and Magee, P.N. (1999). Dietary zinc deficiency enhances esophageal cell proliferation and N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumor incidence in C57BL/6 mouse. Cancer Lett. 143: 63-69.
27. Fong, L.Y.Y., Fidanza, V., Zanesi, N., Lock, L.F., Siracusa, L.D., Mancini, R., Siprashvili, Z., Ottey, M., Martin, S.E., Druck, T., McCue, P.A. and Croce, C.M. (2000) Muir-Torre-like syndrome in Fhit-deficient mice. Proc. Natl. Acad. Sci. USA 97: 4742-4747.
28. Fong, L.Y., Nguyen, V.T. and Farber, J.L. (2001) Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. J. Natl. Cancer Inst. 93: 1525-1533.
29. Gemma, A., Hagiwara, K., Ke, Y., Burke, L.M., Khan, M.A., Nagashima, M., Bennett, W.P. and Harris, C.C. (1997) FHIT mutations in human primary gastric cancer. Cancer Res. 57: 1435-1437.
30. Gemmill, R.M., West, J.D., Boldog, F., Tanaka, N., Robinson, L.J., Smith, D.I., Li, F. and Drabkin, H.A. (1998) The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc. Natl. Acad f Sci. USA 95: 9572-9577.
31. Geradts, J., Fong, K.M., Zimmerman, P.V. and Minna, J.D. (2000) Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathologicall features. Br. J. Cancer 82: 1191-1197.
32. Gotte, K., Hadaczek, P., Coy, J.F., Wirtz, H.W., Riedel, F., Neubauer, J. and Hormann, K. (2000) Fhit expression is absent or reduced in a subset of primary head and neck cancer. Anticancer Res. 20(2A): 1057-1060.
33. Guo, Z. and Vishwanatha, J.K. (2000) Effect of regulated expression of the fragile histidine triad gene on cell cycle and proliferation. Mol. Cell Biochem. 204: 83-88.
34. Heerema, N.A. (1998) Chromosomes in lymphomas and solid tumors. Cancer Invest. 16: 183-187.
35. Ho, W.L., Chang, J.W., Tseng, R.C., Chen, J.T., Chen, C.Y., Jou, Y.S. and Wang, Y.C. (2002) Loss of heterozygosity at loci of candidate tumor suppressor genes in microdissected primary non-small cell lung cancer. Cancer Detect Prev. 26: 343-349.
36. Holbach, L.M., Von Moller, A., Decker, C., Junemann, A.G., Rummelt-Hofmann, C. and Ballhausen, W.G. (2002) Am. J. Ophthalmol. 134: 147-148.
37. Huebner, K., Hadaczek, P., Siprashvili, Z., Druck, T. and Croce, C.M. (1997) The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochem. Biophys. Acta 1332: M62-70.
38. Huebner, K. and Croce, C.M. (2001) FRA3B and other common fragile sites: the weakest link. Nat. Rev. Cancer 1: 214-221.
39. Huiping, C., Kristjansdottir, S., Bergthorsson, J.T., Jonasson, J.G., Magnusson, J., Egilsson, V. and Ingvarsson, S. (2002) High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur. J. Cancer 38: 728-735.
40. Ingvarsson, S., Agnarsson, B.A., Sigbjornsdottir, B.I., Kononen, J., Kallioniemi, O.P., Barkardottir, R.B., Kovatich, A.J., Schwarting, R., Hauck, W.W., Huebner, K. and McCue, P.A. (1999) Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res. 59: 2682-2689.
41. Inoue, H., Ishii, H., Alder, H., Snyder, E., Druck, T., Huebner, K. and Croce, C.M. (1997) Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc. Natl. Acad. Sci. USA 94: 14584-14589.
42. Ishii, H., Dumon, K.R., Vecchione, A., Fong, L.Y., Baffa, R., Huebner, K., Croce, C.M. (2001a) Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. J. Am. Med. Associ. (JAMA) 286: 2441-2449.
43. Ishii, H., Dumon, K., Vecchione, A., Trapasso, F., Mimori, K., Alder, H., Mori, M., Sozzi, G., Baffa, R., Huebner, K. and Carlo M. Croce (2001b) Effect of adenoviral transduction of FHIT into esophageal cancer cells. Cancer Res. 61: 1578-1584.
44. Ishii, H., Zapesi, N., Vecchione, A., Trapasso, F., Yendamuri, S., Sardi, M., Baffa, R., During, M.J., Huebner, K., Fong, Y.Y.L. and Croce, C.M. (2003) Prevention and regression of upper gastric cancer in mice by FHIT gene therapy. FASEB J. in press.
45. Ji, L., Fang, B., Yen, N., Fong, K., Minna, J.D. and Roth, J.A. (1999) Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 59: 3333-3339.
46. Krug, U., Ganser, A. and Koeffler, H.P. (2002) Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21: 3475-3495.
47. Lee, J.I., Soria, J.C., Hassan, K., Liu, D., Tang, X., El-Naggar, A., Hong, W.K. and Mao, L. (2001) Loss of Fhit expression is a predictor of poor outcome in tongue cancer. Cancer Res. 61: 837-841.
48. Lee, S.H., Kim, W.H., Kim, H.K., Woo, K.M., Nam, H.S., Kim, H.S., Kim, J.G. and Cho, M.H. (2001) Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem. Biophys. Res. Commun. 284: 850-855.
49. Liu, Y. and Ganesan, T.S. (2002) Tumour suppressor genes in sporadic epithelial ovarian cancer. Reproduction 123: 341-353.
50. Louhelainen, J., Wijkstrom, H. and Hemminki, K. (2001) Multiple regions with allelic loss at chromosome 3 in superficial multifocal bladder tumors. Intern. J. Oncol. 18: 203-210.
51. Lu, S.H., Montesano, R., Zhang, M.S., Feng, L., Luo, F.J., Chui, S.X., Umbenhauer, D., Saffhill, R. and Rajewsky, M.F. (1986) Relevance of N-nitrosamines to esophageal cancer in China. J. Cell Physiol. Suppl. 4: 51-58.
52. Magee, P.N. (1989) The experimental basis for the role of nitroso compounds in human cancer. Cancer Surv. 8: 207-239.
53. Maruyama, R., Toyooka, S., Toyooka, K.O., Harada, K., Virmani, A.K., Zochbauer-Muller, S., Farinas, A.J., Vakar-Lopez, F., Minna, J.D., Sagalowsky, A., Czerniak, B. and Gazdar, A.F. (2001) Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61: 8659-8663.
54. Maruyama, R., Toyooka, S., Toyooka, K.O., Virmani, A.K., Zochbauer-Muller, S., Farinas, A.J., Minna, J.D., McConnell, J., Frenkel, E.P. and Gazdar, A.F. (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 8: 514-519.
55. Mathiak, M., Rutten, A., Mangold, E., Fischer, H.P., Ruzicka, T., Friedl, W., Propping, P. and Kruse, R (2002) Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am. J. Surg. Pathol. 26: 338-343.
56. Menin, C., Santacatterina, M., Zambon, A., Montagna, M., Parenti, A., Ruol, A. and D'Andrea, E. (2000) Anomalous transcripts and allelic deletions of the FHIT gene in human esophageal cancer. Cancer Genet. Cytogenet. 119: 56-61.
57. Michael, D., Beer, D.G., Wilke, C.W., Miller, D.E. and Glover, T.W. (1997) Frequent deletions of FHIT and FRA3B in Barrett's mataplasia and esophageal adenocarcinomas. Oncogene 15: 1653-1659.
58. Mimori, K., Druck, T., Inoue, H., Alder, H., Berk, L., Mori, M., Huebner, K. and Croce, C.M. (1999) Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc. Natl. Acad. Sci. USA 96: 7456-7461.
59. Mimori, K., Inoue, H., Shiraishi, T., Matsuyama, A., Mafune, K., Tanaka, Y. and Mori, M. (2003) Microsatellite instability is often observed in esophageal carcinoma patients with allelic loss in the FHIT/FRA3B locus. Oncology 64: 275-279.
60. Mineta, H., Miura, K., Takebayashi, S., Misawa, K., Ueda, Y., Suzuki, I, Ito, M. and Wennerberg, J. (2003) Low expression of fragile histidine triad gene correlates with high proliferation in head and neck squamous cell carcinoma. Oral Oncol. 39: 56-63.
61. Mori, M., Mimori, K., Shiraishi, T., Alder, H., Inoue, H., Tanaka, Y., Sugimachi, K., Huebner, K. and Croce, C.M. (2000) Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res. 60: 1177-1182.
62. Mori, M., Mimori, K., Masuda, T., Yoshinaga, K., Yamashita, K., Matsuyama, A. and Inoue, H. (2001) Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma. Cancer Res. 61: 7379-7382.
63. Nelson, H.H., Wiencke, J.K., Gunn, L., Wain, J.C., Christiani, D.C. and Kelsey, K.T. (1998) Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res. 58: 1804-1807.
64. Noguchi, T., Muller, W., Wirtz, H.C., Willers, R. and Gabbert, H.E. (1999) FHIT gene in gastric cancer: association with tumour progression and prognosis. J. Pathol. 188: 378-381.
65. Ohta, M., Inoue, H., Cotticelli, M.G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., Croce, C.M. and Huebner, K. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597.
66. Otterson, G.A., Xiao, G.-H., Geradts, J., Jin, F., Chen, W.-d., Niklinska, W., Kaye, F.J. and Yeung, R.S. (1998) Protein expression and functional analysis of the FHIT gene in human tumor cells. J. Natl. Cancer Inst. 90: 426-432.
67. Ozols, R. (1994) Esophageal cancer. Curr. Problems Cancer XVIII: 191-246.
68. Pace, H.C., Garrison, P.N., Robinson, A.K., Barnes, L.D., Draganescu, A., Rosler, A., Blackburn, G.M., Siprashvili, Z., Croce, C.M., Huebner, K. and Brenner, C. (1998) Genetic, biochemical and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Proc. Natl. Acad. Sci. USA 95: 5484-5489.
69. Pekarsky, Y., Campiglio, M., Siprashvili, Z., Druck, T., Sedkov, Y., Tillib, S., Draganescu, A., Wermuth, P., Rothman, J.H., Huebner, K., Buchberg, A.M., Mazo, A., Brenner, C. and Croce, C.M. (1998) Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA 95: 8744-8749.
70. Philipp-Staheli, J., Payne, S.R. and Kemp, C.J. (2001) p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp. Cell Res. 264: 148-168.
71. Popovici, C., Basset, C., Bertucci, F., Orsetti, B., Adelaide, J., Mozziconacci, M.J., Conte, N., Murati, A., Ginestier, C., Charafe-Jauffret, E., Ethier, S.P., Lafage-Pochitaloff, M., Theillet, C., Birnbaum, D. and Chaffanet, M. (2002) Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. Gene. Chrom. Cancer 35: 204-218.
72. Pylkkanen, L., Wolff, H., Stjernvall, T., Tuominen, P., Sioris, T., Karjalainen, A., Anttila, S. and Husgafvel-Pursiainen, K. (2002) Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients. Int. J. Oncol. 20: 285-290.
73. Rocco, A., Schandl, L., Chen, J., Wang, H., Tulassay, Z., McNamara, D., Malfertheiner, P. and Ebert, M.P. (2003) Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J. Cancer Res. Clin Oncol. 129: 84-88.
74. Ruiz, J., Mazzolini, G., Sangro, B., Qian, C. and Prieto, J. (2001) Gene therapy of hepatocellular carcinoma. Digest. Disease. 19: 324-332.
75. Salomoni, P. and Pandolfi, P.P. (2002) The role of PML in tumor suppression. Cell 108: 165-170.
76. Sato, H., Hiyama, K., Ishioka, S., Maeda, H. and Yamakido, M. (1999) Alternative splicing, but not allelic loss, of the FHIT gene increases with development of lung cancer. Intern. J. Oncol. 15: 81-88.
77. Schichman, S.A., Canaani, E. and Croce, C.M. (1995). Self-fusion of the ALL1 gene. A new genetic mechanism for acute leukemia. J. Am. Med. Associ. (JAMA) 273: 571-576.
78. Serleth, H.J. and Kisken, W.A. (1998) A Muir-Torre syndrome family. Am. Surgeon 64: 365-369.
79. Shi, Y., Zou, M., Farid, N.R. and Paterson, M.C. (2000) Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem. J. 352 Pt 2: 443-448.
80. Shimada, Y., Sato, F., Watanabe, G., Yamasaki, S., Kato, M., Maeda M. and Imamura, M. (2000) Loss of fragile histidine triad gene expression is associated with progression of esophageal squamous cell carcinoma, but not with the patients prognosis and smoking history. Cancer 89: 5-11.
81. Shiraishi, T., Druck, T., Mimori, K., Flomenberg, J., Berk, L., Alder, H., Miller, W., Huebner, K. and Croce, C.M. (2001) Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit. Proc. Natl. Acad. Sci. USA 98: 5722-5727.
82. Siprashvili, Z., Sozzi, G., Barnes, L.D., McCue, P., Robinson, A.K., Eryomin, V., Sard, L., Tagliabue, E., Greco, A., Fusetti, L., Schwartz, G., Pierotti, M.A., Croce, C.M. and Huebner, K. (1997) Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. USA 94: 13771-13776.
83. Skopelitou, A.S., Gloustianou, G., Bai, M. and Huebner, K. (2001) FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo 15: 169-173.
84. Soussi, T. (1996) The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol. Med. Today 2: 32-37.
85. Sozzi, G., Veronese, M.L., Negrini, M., Baffa, R., Cotticelli, M.G., Inoue, H., Tornielli, S., Pilotti, S., De Gregorio, L., Pastorino, U., Pierotti, M.A., Ohta, M., Huebner, K. and Croce, C.M. (1996) The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85: 17-26.
86. Sozzi, G., Sard, L., De Gregorio, L., Marchetti, A., Musso, K., Buttitta, F., Tornielli, S., Pellegrini, S., Veronese, M.L., Manenti, G., Incarbone, M., Chella, A., Angeletti, C.A., Pastorino, U., Huebner, K., Bevilaqua, G., Pilotti, S., Croce, C.M. and Pierotti, M.A. (1997) Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 57: 2121-2123.
87. Sozzi, G., Huebner, K. and Croce, C.M. (1998a) FHIT in human cancer. Adv. Cancer Res. 74: 141-166.
88. Sozzi, G., Pastorino, U., Moiraghi, L., Tagliabue, E., Pezzella, F., Ghirelli, C., Tornielli, S., Sard, L., Huebner, K., Pierotti, M.A., Croce, C.M. and Pilotti, S. (1998b) Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 58: 5032-5037.
89. Stein, C.K., Glover, T.W., Palmer, J.L. and Glisson, B.S. (2002) Direct correlation between FRA3B expression and cigarette smoking. Gene. Chrom. Cancer 34: 333-340.
90. Steinmetz, K.A. and Potter, J.D. (1991) Vegetables, fruit and cancer. I. Epidemiology. Cancer Causes Control 2: 325-357.
91. Struski, S., Doco-Fenzy, M. and Cornillet-Lefebvre, P. (2002) Compilation of published comparative genomic hybridization studies. Cancer Genet. Cytogenet. 135: 63-90.
92. Tamura, G., Sakata, K., Nishizuka, S., Maesawa, C., Suzuki, Y., Iwaya, T., Terashima, M., Saito, K. and Satodate, R. (1997) Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Gene. Chrom. Cancer 20: 98-102.
93. Tamura, G. (2002) Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol. Histopathol. 17: 323-329.
94. Tanaka, H., Shimada, Y., Harada, H., Shinoda, M., Hatooka, S., Imamura, M. and Ishizaki, K. (1998) Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res. 58: 3429-3434.
95. Tomizawa, Y., Nakajima, T., Kohno, T., Saito, R., Yamaguchi, N. and Yokota, J. (1998) Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res. 58: 5478-5483.
96. Trapasso, F., Krakowiak, A., Cesari, R., Arkles, J., Yendamuri, S., Ishii, H., Vecchione, A., Kuroki, T., Bieganowski, P., Pace, H.C., Huebner, K., Croce, C.M. and Brenner, C. (2003) Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc. Natl. Acad. Sci. USA 100: 1592-1597.
97. Tseng, J.E., Kemp, B.L., Khuri, F.R., Kurie, J.M., Lee, J.S., Zhou, X., Liu, D., Hong, W.K. and Mao, L. (1999) Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res. 59: 4798-4803.
98. Tsujiuchi, T., Sasaki, Y., Murata, N., Tsutsumi, M., Konishi, Y. and Nakae, D. (2001) FHIT alterations in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Carcinogenesis 22: 2017-2022.
99. Tsujiuchi, T., Sasaki, Y., Kubozoe, T., Tsutsumi, M., Konishi, Y. and Nakae, D. (2002) Alterations of the Fhit gene in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Mol. Carcinog. 34: 19-24.
100. Turner, B.C., Ottey, M., Zimonjic, D.B., Potoczek, M., Hauck, W.W., Pequignot, E., Keck-Waggoner, C.L., Sevignani, C., Aldaz, C.M., McCue, P.A., Palazzo, J., Huebner, K. and Popescu, N.C. (2002) The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res. 62: 4054-4060.
101. Uematsu, K., Yoshimura, A., Gemma, A., Mochimaru, H., Hosoya, Y., Kunugi, S., Matsuda, K., Seike, M., Kurimoto, F., Takenaka, K., Koizumi, K., Fukuda, Y., Tanaka, S., Chin, K., Jablons, D.M. and Kudoh, S. (2001) Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res. 61: 8527-8533.
102. Ushida, J., Sugie, S., Kawabata, K., Pham, Q.V., Tanaka, T., Fujii, K., Takeuchi, H., Ito, Y. and Mori, H. (2000) Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. J. J. Cancer Res. 91: 893-898.
103. van Heerden, W.F., Swart, T.J., van Heerden, M.B., van Rensburg, E.J., Engelbrecht, S., Dreyer, L. and Huebner, K. (1999) Immunohistochemical evaluation of Fhit protein expression in oral squamous cell carcinomas. J. Oral Path. Med. 28: 433-437.
104. Virgilio, L., Shuster, M., Gollin, S.M., Veronese, M.L., Ohta, M., Huebner, K. and Croce, C.M. (1996) FHIT gene alterations in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 93: 9770-9775.
105. Wada, T., Louhelainen, J., Hemminki, K., Adolfsson, J., Wijkstrom, H., Norming, U., Borgstrom, E., Hansson, J. and Steineck, G. (2001) The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction. BJU International 87: 876-881.
106. Wargovich, M.J. and Imada, O. (1993) Esophageal carcinogenesis in the rat: a model for aerodigestive tract cancer. J. Cell Biochem. Suppl. 17F: 91-94.
107. Werner, N.S., Siprashvili, Z., Fong, L.Y.Y., Marquitan, G., Schroder, J.K., Bardenheuer, W., Seeber, S., Huebner, K., Schutte, J. and Opalka, B. (2000) Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogeneous Fhit expression. Cancer Res. 60: 2780-2785.
108. Wu, R., Connolly, D.C., Dunn, R.L. and Cho, K.R. (2000) Restored expression of fragile histidine triad protein and tumorigenicity of cervical carcinoma cells. J. Natl. Cancer Inst. 92(4): 338-344.
109. Yang, C.S. (1980) Research on esophageal cancer in China: a review. Cancer Res. 40(8 Pt 1): 2633-2644.
110. Yunis, J.J. and Soreng, A.L. (1984) Constitutive fragile sites and cancer. Science 226: 1199-1204.
111. Zanesi, N. and Croce, C.M. (2001a) Fragile histidine triad gene and skin cancer. Eur. J. Dermatol. 11: 401-404.
112. Zanesi, N., Fidanza, V., Fong, L.Y., Mancini, R., Druck, T., Valtieri, M., Rudiger, T., McCue, P.A., Croce, C.M. and Huebner, K. (2001b) The tumor spectrum in FHIT-deficient mice. Proc. Natl, Acad. Sci. USA 98: 10250-10255.
113. Zochbauer-Muller, S., Fong, K.M., Maitra, A., Lam, S., Geradts, J., Ashfaq, R., Virmani, A.K., Milchgrub, S., Gazdar, A.F. and Minna, J.D. (2001) 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 61: 3581-3585.